A recently published study has reported robust CD4 and CD8 T cell response to the SARS-CoV-2 vaccine in MS patients under BCDT (36) who also had selective defects in antigen-specific circulating TFH, preserved TH1 cell responses and augmented CD8 T cell responses. This evidence concerns the gene CD8A and myeloid sarcoma.